Recombinant HEK293 cell line expressing full length human CD40 (Tumor necrosis factor receptor superfamily member 5; TNFRSF5). Expression is confirmed by real-time qPCR and Western Blot. This NF-kappaB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-kappaB response element located upstream of the TATA promoter. Following activation by human CD40 ligand, NF-kappaB transcription factor binds to the DNA response elements to induce transcription of the luciferase gene.
Mycoplasma testing: This cell line has been screened using the MycoAlert Mycoplasma Detection Kit (Lonza, Cat.#LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set(Lonza, Cat. #LT07-518) was used as a positive control.
Host Species: human
Background
CD40, a TNF receptor superfamily member, was initially identified on B lymphocytes. Antigen presenting cells (APCs) such as monocytes, basophils, dendritic cells, have been found to express CD40. Additionally, CD40 has been identified in non-immune cells such as endothelial cells and epithelial cells. A wide variety of carcinoma cells over-express CD40 as well. Interaction with CD40 ligand (CD40L, CD154) on CD4+ T helper lymphocytes triggers the expression of intercellular adhesion molecule (ICAM) and other pro-inflammatory cytokines. CD40:CD40L signaling simultaneously increases activation of antigen-specific T cells. CD40 activates NF-kappaB-dependent signaling in response to lipopolysaccharide (LPS) found on Gram negative bacterial pathogens. Furthermore, agonistic CD40 monoclonal antibodies have been shown to activate antigen presenting cells (APC) and promote anti-tumor T-cell responses in addition to fostering cytotoxic myeloid cells with the potential to control cancer in the absence of T-cell immunity.
Application
The CD40 NF-kappaB Reporter HEK293 Stable Cell Line is ideal for High Throughput Screening (HTS) to identify potential CD40 agonistic monoclonal antibodies and CD40-specific inhibitors.
License Disclosure: Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of Biohippo products to your laboratory. Biohippo does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact [email protected] for details. Publications using this cell line should reference Biohippo Inc. Warning: Avoid freeze/thaw cycles.
Product Format
Each vial contains ~2 x 106 cells in 1mL of 10% DMSO in FBS.
Storage Stability
Immediately upon receipt, store vials in liquid nitrogen.
Reference
1. Li G et.al. (2013) Human Genetics in Rheumatoid Arthritis Guides a High-Throughput Drug Screen of the CD40 Signaling Pathway. PLoS Genet. 9: e1003487. 2. Pontrelli P et.al. (2006) CD40L Proinflammatory and Profibrotic Effects on Proximal Tubular Epithelial Cells: Role NF-kappaB and Lyn. J. Amer. Soc. Neph. 17: 627. 3. Lavorgna A et.al. (2014) A Critical Role for IL-17RB Signaling in HTLV-1 Tax-Induced NF-kappaB Activation and T-Cell Transformation. PLoS Path. 10: e1004418.4. Moschonas A et.al. (2012) CD40 Stimulates a "Feed-Forward" NF-kappaB- Driven Molecular Pathway That Regulates IFN-beta Expression in Carcinoma Cells. J. Immunol. 188: 5521.